期刊文献+

阿托伐他汀经ERK信号转导通路抑制CD40L诱导的内皮细胞E-选择素的表达 被引量:2

Inhibition of CD40L induced E-selectin expression in endothelial cells through extracellular signalregulated kinase signaling pathway
原文传递
导出
摘要 目的探讨阿托伐他汀对CD40L诱导人脐静脉内皮细胞(HUVEC)表达E-选择素的影响及其信号转导通路的关系。方法原代培养HUVEC,给予CD40L刺激和不同浓度阿托伐他汀干预。应用反转录聚合酶链反应(RT—PCR)和流式细胞术分别检测阿托伐他汀对CD40L诱导的HUVEC的E-选择素mRNA和细胞表面E-选择素表达情况。同时通过蛋白印迹法检测细胞外信号调节激酶(ERK1/2)蛋白磷酸化的表达。结果0.1、1、10μmol/L阿托伐他汀可浓度依赖性下调CD40L诱导的HUVECE-选择素mRNA及蛋白的表达。1μmol/L阿托伐他汀可使E-选择素蛋白下调48.68%,10μmol/L阿托伐他汀可使E-选择素蛋白下调70.25%。同时不同浓度阿托伐他汀均能抑制CD40L诱导的ERK1/2磷酸化水平,其表达分别下调至CIMOL刺激组的81%±6%、73%±5%和41%±5%。结论阿托伐他汀能通过ERK1/2信号转导通路抑制CD40L诱导的内皮细胞E-选择素表达。 Objective To investigate the regulatory effects of atorvastatin on CD40L induced E- seleetin expression in endothelial cells and the association thereof with signal pathway. Methods Human umbilical vein endothelial cells (HUVECs) were obtained from umbilical cord newly delivered and incubated with CD40L for 24 hours with or without pretreated by atorvastatin of the concentrations of 0. 1, 1, or 10 μmol/L. The protein and mRNA levels of E-selectin were detected by flow cytometry and reverse transcription polymerase chain reaction (RT-PCR) respectively. The extracellular signal regulated kinase (ERK) 1/2 activation was analyzed by Western blotting. Results The E-selectin mRNA expression level of the HUVECs treated by atorvastatin was lower than that of the CD40L stimulation group by 33.33% when the atorvastatin concentration was 1 μmol/L, and was lower by 45.16% when the atorvastatin concentration was 10 μmol/L. The E-selectin protein expression level of the HUVECs treated by atorvastatin was lower than that of the CD40L stimulation group by 48.68% when the atorvastatin concentration was 1 μmot/L, and was lower by 70. 25% when the atorvastatin concentration was 10 μmoL/L. The phosphorylation level of ERK1/2 was enhanced by CD40L stimulation and the CD40L induced phosphorylation of ERK1/2 decreased by 81% ±6% ,73% ± 5%, and 41% ±5% respectively after atorvastatin stimulation. Conclusion Atorvastatin decreases the CD40L induced E-selectin expression in endothelial cells while atorvastatin at 0. 1 - 10 μmol/L concentration-dependently through inhibiting the activation of ERK1/2.
出处 《中华医学杂志》 CAS CSCD 北大核心 2008年第48期3432-3435,共4页 National Medical Journal of China
基金 湖北省自然科学基金资助项目(2003ABA183)
关键词 E选择素 有丝分裂素激活蛋白激酶类 CD40配体 人脐静脉内皮细胞 阿托伐他汀 E-selectin Mitogen-activated protein kinases CD40 ligand Human umbilical vein endothelial cells AtonTastatin
  • 相关文献

参考文献10

  • 1Libby P. Inflammation in atherosclerosis. Nature, 2002, 420 : 868-874.
  • 2Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298:1911-1912.
  • 3Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340: 115-126.
  • 4Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res, 2001, 89:1092-1103.
  • 5Phipps RP. Atherosclerosis : the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA, 2000, 97 : 6930-6932.
  • 6Lutgens E,Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med, 1999, 5: 1313- 1316.
  • 7Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature, 1998, 394:200-203.
  • 8Alber HF, Frick M, Suessenbacher A, et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease-a randomized, placebo-controlled study. Am Heart J, 2006, 151 : 139.
  • 9Marzio PD, Sherry B, Thomas EK, et al. Beta-chemokine production in CD40L-stimulated monocyte-derived macrophages requires activation of MAPK signaling pathways. Cytokine, 2003, 23 : 53-63.
  • 10Riad A, Du J, Stiehl S, et al. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol, 2007, 569:204-211.

同被引文献29

  • 1李莹,陈志红,周北凡,李义和,武阳丰,刘小清,赵连成,麦劲壮,杨军,石美玲,田秀珍,关渭全,于学海,陈磊.血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用[J].中华心血管病杂志,2004,32(7):643-647. 被引量:329
  • 2黄晓红,孙凯,宋燕,张红叶,杨瑛,惠汝太.α-内收蛋白基因及G蛋白β3亚单位基因多态与原发性高血压的关系[J].中华医学杂志,2007,87(24):1682-1684. 被引量:9
  • 3Meisinger C,Doring A,Thorand B,et al.Body fat distribution and risk of type 2 diabetes in the general population:are there differences between men and women? The MONICA/KORA Augsburg cohort study[J].Am J Clin Nutr,2006,84(3):483-489.
  • 4Ito MK,Talbert RL,Tsimikas S.Statin-associated pleiotropy:possible neneficial effects beyond cholesterol reduction[J].Pharmacotherapy,2006,26(7Pt2):85s-97s.
  • 5Patti G,Nusca A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronany intervention[J].Am J Cardiol,2008,101(3):279-285.
  • 6Ichiki T,Takeda K,Tokunou T,et al.Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells[J].Arterioscler Thromb Vasc Biol,2001,21(12):1896-1901.
  • 7Chello M,Goffredo C,Patti G,et al.Effects of atorvastatin on arterial endothelial function in coronary bypass surgery[J].Eur J Cardiothorac Surg,2005,28(6):805-810.
  • 8Mason JC,Ahmed Z,Mankoff R,et al.Statin-induced expression of decay-accelerating factor protects vascular endothelial against complement-mediated injury[J].Circ Res,2002,91(8):696-703.
  • 9Bonnet J,Mcpherson R,Tedgni A,et al.Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study[J].Clin Ther,2008,30(12):2298-2313.
  • 10卫生部心血管病防治研究中心.2005年中国心血管病报告[M].北京:中国大百科全书出版社,2006:1-4.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部